

1 **International attitudes on COVID-19 vaccination: repeat national cross-**
2 **sectional surveys across 15 countries**

3

4

5 Roberto Fernandez Crespo¹; Manar Shafat²; Natalie Melas-Kyriazi¹; Lisa Gould¹; Sarah
6 Jones¹; Ana Luisa Neves¹; Melanie S Leis¹; Hendramoorthy Maheswaran¹; Ara Darzi¹

7

8

9 1. Institute of Global Health Innovation, Imperial College London, London, UK

10 2. UCL Cancer Institute, University College London, London, UK

11

12

13

14

15

16

17 **Address for correspondence:**

18 Dr Hendramoorthy Maheswaran

19 Institute of Global Health Innovation

20 Imperial College London

21 London

22 Email: h.maheswaran@imperial.ac.uk

23

24

25

26

27

28

29 **Key words:** Covid-19; Vaccination; Hesitancy; Surveys, Global Health

30

31 Word count, text: 2452

32 Word count, abstract: 272

33 Tables: 3

34 Figures: 4

35

36 **Abstract**

37 **Objective:** To examine the general public's views around willingness to receive COVID-19
38 vaccines and concerns regarding their safety.

39 **Design:** Repeat cross-sectional surveys.

40 **Setting:** Online surveys in Australia, Canada, Denmark, Finland, France, Germany, Italy,
41 Japan, Netherlands, Norway, Singapore, South Korea, Spain, Sweden and the United
42 Kingdom

43 **Participants:** National samples of adults aged ≥ 18 years in November 2020 and January
44 2021.

45 **Main outcomes measures:** The proportion of adults reporting: willingness to receive a
46 COVID-19 vaccination; concern regarding side-effects from vaccinations; concerns over
47 contraction COVID-19, and beliefs around vaccine provision in their country. Changes
48 between the November and January surveys are also reported.

49 **Results:** Across the 15 countries, the proportion of respondents reporting they would have
50 the COVID-19 vaccine increased from 40.7% (range: 25.0-55.1) to 55.2% (range: 34.8-77.5),
51 proportion reporting worried about the side-effects of vaccine decreased from 53.3% (range:
52 42.1-66.7) to 47.9% (range: 28.0-66.1). On the second survey, willingness to receive vaccine
53 remained low in females (49.4%, range: 30.2-79.1), aged 18-39 years (42.1%, range: 25.9-
54 71.7), those not working or unemployed (48.9, range: 18.8-67.0), students (45.9%, range:
55 22.8-70.0), and those with children at home (46.5%, range: 32.4-68.9). Concerns regarding
56 safety of vaccine remained high in females (53.7%, range: 31.8-70.4), aged 18-39 years
57 (50.8%, range: 28.2-60.7), aged 40-64 years (51.3%, range: 30.7-68.5), those working
58 (50.5%, range: 26.7-65.0), those not working or unemployed (53.3, range: 35.4-73.8) and
59 those with children at home (55.8%, range: 36.5-64.7).

60 **Conclusion:** COVID-19 vaccine hesitancy decreased considerably over a relatively short
61 time coinciding with the discovery of effective vaccines. The public remain concerned about
62 their safety, and public health messaging will need to emphasis their safety especially
63 amongst females, parents and younger adults.

64

65

66

67

68

69

70

71 **Introduction**

72 The discovery of multiple effective vaccines against COVID -19 offers a path out of the
73 global pandemic that has already taken over 2 million lives. Success of global vaccination
74 will depend on achieving herd immunity, from individuals acquiring immunity through
75 vaccination or after infection. For COVID-19 this may require more than three thirds of
76 populations receiving an effective vaccine¹. However, there are concerns that many
77 individuals are reluctant to get a COVID-19 vaccine, with reasons ranging from concerns
78 regarding their safety to perceptions of a low personal risk of severe illness²⁻⁴. Studies
79 undertaken prior to the discovery of effective vaccines have found up to a third of the
80 population may be resistant or hesitant to COVID-19 vaccination^{2,5,6}.

81

82 In this study we sought to examine people's willingness to receive the COVID-19 vaccine
83 and whether vaccine hesitancy had reduced after effective vaccines were discovered and
84 provided in many countries. Additionally, we explored respondents' perceptions about
85 vaccine safety, and their views on whether their government would be able to deliver mass
86 vaccination. We were able to compare changes in attitudes in this data from November 2020
87 to January 2021. We use repeated cross-sectional nationally representative data collected
88 from 15 countries; and explored how these views differ and have changed across different
89 socio-demographic groups and higher risk individuals.

90

91

92 **Methods**

93 **Participants and procedures**

94 This study uses two waves of nationally representative data collected by YouGov in 15
95 countries (Australia; Canada; Denmark; Finland; France; Germany; Italy; Japan; Netherlands;
96 Norway; Singapore; South Korea; Spain; Sweden; United Kingdom). These cross-sectional
97 surveys were started in April 2020 to capture health behaviour and public perceptions around
98 COVID-19 and are repeated every two weeks. For each country and survey, YouGov samples
99 a nationally representative population to complete surveys online, from a larger panel of
100 respondents in each country. YouGov generates survey weights to adjust the samples to be
101 nationally representative.

102

103 The survey consists of a core set of demographic questions and additional questions relating
104 to COVID-19 and preventative measures to curtail the pandemic. Since November 2020,
105 respondents have been asked about their views on COVID-19 vaccination. This study is
106 based on data collected when these questions were introduced (9-15th November 2020) and
107 the most recent survey undertaken in each country (11th January 2021 to 31st January 2021).

108

109 **Measures**

110 The main outcome measures included in this analysis related to respondents' responses to
111 four COVID-19 related questions. The questions asked respondents to what extent they
112 agreed or disagreed with the statements; (1) *I am worried about getting COVID-19*; (2) *If a*
113 *COVID-19 vaccine were made available to me this week, I would definitely get it*; (3) *I am*
114 *worried about potential side effects of a COVID-19 vaccine*; (4) *I believe government health*
115 *authorities in my country will provide me with an effective COVID-19 vaccine*. Respondents
116 were asked to indicate their response on a scale between 1 (strongly agreed) and 5 (strongly
117 disagreed).

118

119 Sex, age and employment status were reported by survey respondents. Respondents were
120 asked whether they had any one of the following health conditions: Arthritis; Asthma;
121 Cancer; Cystic fibrosis; Chronic obstructive pulmonary disease; Diabetes; Epilepsy; Heart
122 disease; High blood pressure; High cholesterol; HIV/AIDS; Mental health condition;
123 Multiple Sclerosis. Respondents who responded 'yes' to any of these conditions were
124 classified as having long-term health condition. Additional categories for this variable
125 included: No; prefer not to say. Respondents were asked if they lived with children under the
126 age of 18.

127

128 Respondents were asked whether they worked outdoors (construction; delivering to homes;
129 food retail; healthcare; logistics or other transportation; manufacturing; policing or prisons;
130 public transport; school; social care) in the week of the survey. Responses were re-
131 categorised as whether or not respondent was a frontline worker (yes; no; other/not sure).

132

133 **Data analysis**

134 We analysed the data for each country separately and used the survey weights to account for
135 differential probabilities for selection to the survey. Responses to the four questions on
136 Covid-19 were recoded as a dichotomous response of agree (strongly agree/1; or 2) and not

137 agree (strongly disagreed/5; 4; or 3). We present descriptive analyses (percentage agree) for
138 the whole country, and by sex, age group (18-39 years; 40-65 years; ≥ 65 years);
139 employment status (working; retired; student; not working/unemployed); have children at
140 home (yes; no prefer not to say); long-term health condition (yes; no; prefer not to say), and
141 frontline worker (yes; no; other/not sure).

142

143 We present the mean percentage change and 95% confidence interval within each country,
144 between responses in the first wave of surveys (9-15th November 2020) and the second wave
145 of surveys (11th-31st January 2021). We classified this change in percentage as increased
146 ($>5\%$; 0-5%); or decreased ($>5\%$; 0-5%). We also present the median and low/high
147 percentage of respondents who agreed, across the sample of 15 countries on each survey date.

148

149

150 **Results**

151 Table 1 shows the survey dates for the 15 countries and number of respondents sampled on
152 each occasion. For all 15 countries the first surveys were undertaken between 9th and 15th
153 November 2020 and the second surveys undertaken between 11th and 31st January 2021. The
154 number of respondents sampled in each country, on each survey, ranged from 483 to 1032.
155 12/15 countries had commenced their COVID-19 vaccination programmes prior to the
156 second survey.

157

158 Table 2 displays the proportion of respondents in each country that agreed with each of the
159 four questions on COVID-19, and the percentage change between the two surveys. Table 3
160 displays the median estimate for the sample of 15 countries, for the whole population and
161 across different population sub-groups. More detailed country-level data is provided in the
162 Appendix. In 10/15 countries there was a significant increase in the proportion of respondents
163 reporting they were worried about getting COVID-19 between the two surveys (Table 2), for
164 3/15 countries this increase was at least 5% (Figure 1). Across the 15 countries the median
165 proportion of respondents that reported being worried about getting COVID-19 in the first
166 and second surveys was 41.1% (range: 28.7-67.3) and 41.8% (range: 34.6-69.9), respectively
167 (Table 3).

168

169 Across the 15 countries the median estimate for the proportion of respondents that reported
170 they would have the Covid-19 vaccine in the first and second surveys was 40.7% (range:
171 25.0-55.1) and 55.2% (range: 34.8-77.5), respectively (Table 3). In 12/15 countries there was
172 a significant increase in the proportion of respondents who reported they would have a
173 vaccine (Table 2), for 11/15 countries this increase was at least 5% (Figure 2). In 3/15
174 countries (Australia, Singapore and South Korea) there was a significant decrease in the
175 proportion that reported they would have the vaccine. Across all population sub-groups, the
176 median estimate for the proportion reporting they would have a vaccine increased between
177 the two surveys (Table 3). On the second survey, the median proportion that reported they
178 would have a vaccine remained below 50% amongst females (49.4%, range: 30.2-79.1), those
179 aged 18-39 years (42.1%, range: 25.9-71.7), those not working or unemployed (48.9, range:
180 18.8-67.0), students (45.9%, range: 22.8-70.0), those with children at home (46.5%, range:
181 32.4-68.9) and those without long-term health condition (47.5%, range: 32.3-72.4). This
182 means that for at least half the 15 countries, less than half of those sampled in these groups
183 would have the COVID-19 vaccine.

184

185 Across the 15 countries the median proportion of respondents that reported they were worried
186 about the side-effects of a COVID-19 vaccine in the first and second surveys was 53.3%
187 (range: 42.1-66.7) and 47.9% (range: 28.0-66.1), respectively (Table 3). In 11/15 countries
188 there was a significant decrease in the proportion of respondents who reported they were
189 worried about the side-effects of a vaccine (Table 2), for 10/15 countries this decrease was at
190 least 5% (Figure 3). In 4/15 countries (Australia, Japan, Singapore and South Korea) there
191 was a significant increase in the proportion that reported they were worried about the side-
192 effects of a vaccine. On the second survey, the median proportion of respondents that
193 reported they were worried about side-effects of a vaccine remained above 50% amongst
194 females (53.7%, range: 31.8-70.4), those aged 18-39 years (50.8%, range: 28.2-60.7), those
195 aged 40-64 years (51.3%, range: 30.7-68.5), those that were working (50.5%, range: 26.7-
196 65.0), those not working or unemployed (53.3, range: 35.4-73.8), those with children at home
197 (55.8%, range: 36.5-64.7) and those that were not frontline workers (51.4%, range: 30.2-
198 65.0). This means that for at least half the 15 countries, more than half of those sampled in
199 these groups were worried about the side-effects of a COVID-19 vaccine.

200

201 Across the 15 countries the median proportion of respondents that reported they believed
202 their government health authority would provide them the COVID-19 vaccine in the first and

203 second surveys was 49.4% (range: 36.3-64.2) and 55.0% (range: 38.1-72.6), respectively
204 (Table 2). In 12/15 countries there was a significant increase in the proportion of respondents
205 that reported they believed their government health authority would provide a vaccine (Table
206 2), for 9/15 countries this increase was least 5% (Figure 4). On the second survey, the median
207 proportion that reported they believed their Government would provide the COVID-19
208 vaccine remained relatively low amongst those aged 18-39 years (49.8%, range: 30.1-64.8).

209
210

211 **Discussion**

212 This study found willingness to receive a COVID-19 vaccination varied widely across the 15
213 countries, ranging from 34.8% to 77.5%. However, in all but three of the 15 countries the
214 proportion of respondents who stated they would receive the vaccine increased by more than
215 5%, over a relatively short time period that coincided with the discovery and roll-out of
216 effective vaccines. In several countries this increase was over 20%. Two of the three
217 countries, where willingness to receive the vaccine decreased, had not started vaccinating
218 their residents at the time the second survey was undertaken.

219

220 Previous studies highlight the general public's concerns around the safety of Covid-19
221 vaccines^{7,8}, we found these concerns remain somewhat high, ranging from 28.0% to 66.1%. It
222 is reassuring that in 11 of the 15 countries surveyed, these concerns have fallen considerably
223 and over a relatively short time. Three of the four countries where respondents reported
224 increased concerns regarding the safety of vaccines, also reported decreased willingness to
225 receive the vaccine. In the majority of countries, respondents reported increased confidence
226 their Governments would provide them with an effective vaccine. Two of the three countries
227 where respondents reported decreased had not yet started their vaccination programmes at the
228 time of the second survey.

229

230 An individual's perception around the safety of a COVID-19 vaccine is a strong predictor to
231 whether they would be willing to receive the vaccine⁹. The public may also be hesitant
232 around the vaccine if they perceive the rapid nature of COVID-19 vaccine research and
233 deployment has been at the expense of adequately exploring their safety. The continued high
234 levels of concern amongst the general population with regards to the safety of COVID-19
235 vaccines is worrying and may hinder achieving herd immunity. Many countries are already

236 implementing public health messaging that seeks to alleviate these concerns; and these will
237 increasingly need to be targeted at harder to reach populations. Previous studies have found
238 females, younger, and those unemployed to be less willing to receive a COVID-19 vaccine^{5 6}
239 ⁹. This was consistent with our findings. In the majority of the countries, we found
240 willingness to receive the vaccine increased considerably amongst these population groups.
241 However, these three groups remain the most concerned about the side effects of a COVID-
242 19 vaccine. Vaccination programmes in countries should ensure communications emphasis
243 the safety of the vaccine amongst these population groups.

244

245 The majority of countries have started vaccinating their population by initially targeting
246 higher risk groups; those aged over 65 years and those with long-term health conditions that
247 places them at higher risk of severe infection. It is reassuring to find high and increasing
248 levels of willingness to receive the vaccine, and low and decreasing levels of concern
249 regarding their safety, amongst these populations. These two groups remain the most
250 concerned about contracting COVID-19 infection. In the majority of countries there was
251 increased concerns about contracting COVID-19 infection between the two survey dates.
252 This is likely to reflect the increasing number of cases seen between the two surveys in many
253 of the countries included in this study. Countries will need to continue monitoring this,
254 especially in relation to people's perception around the protection offered by the different
255 vaccines and increasing anxieties around new COVID-19 variants emerging.

256

257 Students attending higher education institutes will likely need a vaccine considering the high
258 risk of COVID-19 clusters and outbreaks¹⁰; whilst those who work in the frontline more
259 likely to be exposed. Parents decide whether their child receives the vaccine, and whilst
260 children have not been found to be at increased risk of severe illness or drive transmission¹¹
261 ¹², vaccination may be needed to prevent school closures. We found relatively low
262 willingness to receive the vaccine and relatively high concerns around their safety in these
263 population groups. Surprisingly these groups also reported lower levels of concern regarding
264 contracting COVID-19 infection. As countries expand the populations being offered the
265 vaccine greater emphasis will need to be taken to ensure parents, younger populations and
266 those that work in the frontline are reached by public health messaging around the need for,
267 and safety in being vaccinated. Evidence-base for effective strategies to tackle vaccine
268 hesitancy is limited and have primarily focussed on childhood vaccines^{13 14}. Strategies
269 implemented will need to tackle individual-level factors, but should not ignore the

270 importance of utilising community, social and religious networks to address vaccine
271 hesitancy¹⁵, and will need to be evaluated.

272

273 Strengths of our study include the large number of countries for which data is presented, as
274 well as the exploration of changes in attitudes towards the vaccine and infection over time.

275 Possible limitations include the cross-sectional nature of the study, relatively small numbers
276 surveyed in each country, predominantly high-income European countries surveyed and the

277 use of online survey panels. These do limit the conclusions that can be drawn, especially
278 around the casual relationship between vaccine hesitancy and concerns about their safety.

279

280 In conclusion, our findings highlight the willingness of the general public to receive a vaccine
281 is growing over time and the populations subgroups that may need to be targeted with

282 tailored public health messaging around the benefits and safety associated with receiving the
283 COVID-19 vaccine. Although in several countries willingness to vaccinate increased

284 considerable, in half the countries surveyed, in many population sub-groups, less than half
285 would have a vaccine and more than half were worried about their' side-effects. Further data

286 is needed to understand attitudes towards COVID-19 vaccines from low- and middle-income
287 countries, especially those in South America, Middle East and Africa. Follow-up surveys will

288 need to be undertaken in these and other countries to monitor longer term changes in public
289 attitudes towards the COVID-19 vaccine if the goal of herd immunity is to be achieved.

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307 **Acknowledgements:** We thank YouGov Plc for providing us the data. YouGov are
308 commissioned by the UK Government to undertake the surveys.

309

310 **Contributors:** RFC, MS, SJ, MSL, HM and AD conceived and designed the study. RFC, MS
311 and NMK did statistical analysis. HM wrote first draft of paper. All authors contributed to
312 data interpretation, revision of paper and contributed to discussion. FRC and HM are the
313 guarantors for this study.

314

315 **Funding:** No sources of funding to disclose.

316

317 **Competing interests:** None to declare. The corresponding author had full access to all the
318 data in the study and had final responsibility for the decision to submit for publication.

319

320 **Ethical approval:** Not needed.

321

322 **Data sharing:** All data for YouGov surveys are deidentified and publicly available from:
323 <https://github.com/YouGov-Data/covid-19-tracker>

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341 **Tables and Figures**

342

343 **Table 1: Description of surveys and countries**

Country	Survey date	Number of Respondents	Vaccination doses administered per 100 people on date of 2 nd survey*
Australia	9 th Nov to 15 th Nov 2020	1001	Not started
	11 th Jan to 17 th Jan 2021	1001	
Canada	9 th Nov to 15 th Nov 2020	1003	1.12
	18 th Jan to 24 th Jan 2021	968	
Denmark	9 th Nov to 15 th Nov 2020	1006	2.03
	11 th Jan to 17 th Jan 2021	1000	
Finland	9 th Nov to 15 th Nov 2020	1001	0.98
	18 th Jan to 24 th Jan 2021	1006	
France	9 th Nov to 15 th Nov 2020	1000	0.69
	18 th Jan to 24 th Jan 2021	1032	
Germany	9 th Nov to 15 th Nov 2020	1000	0.85
	11 th Jan to 17 th Jan 2021	1000	
Italy	9 th Nov to 15 th Nov 2020	1005	2.5
	25 th Jan to 31 st Jan 2021	1004	
Japan	9 th Nov to 15 th Nov 2020	505	Not started
	25 th Jan to 31 st Jan 2021	499	
Netherlands	9 th Nov to 15 th Nov 2020	509	0.86
	25 th Jan to 31 st Jan 2021	504	
Norway	9 th Nov to 15 th Nov 2020	1001	1.51
	25 th Jan to 31 st Jan 2021	1002	
Singapore	9 th Nov to 15 th Nov 2020	1000	0.06
	11 th Jan to 17 th Jan 2021	1001	
South Korea	9 th Nov to 15 th Nov 2020	499	Not started
	18 th Jan to 24 th Jan 2021	483	
Spain	9 th Nov to 15 th Nov 2020	1009	0.87
	11 th Jan to 17 th Jan 2021	1001	
Sweden	9 th Nov to 15 th Nov 2020	1001	2.25
	25 th Jan to 31 st Jan 2021	1000	
United Kingdom	9 th Nov to 15 th Nov 2020	1005	10.79
	25 th Jan to 31 st Jan 2021	1001	

344 *Data extracted from 'Our World in Data'

345

346

347 **Table 2: Percentage ‘agreeing’ with COVID-19 related questions in each of the 15 countries**

Country	% Would vaccinate			% Worried about side effects			% Believe government health authority will provide			% Worried about getting COVID-19		
	Wave 1	Wave 2	Change + 95%CI	Wave 1	Wave 2	Change + 95%CI	Wave 1	Wave 2	Change + 95%CI	Wave 1	Wave 2	Change + 95%CI
Australia	55.1	48.5	-6.6 (-6.6, -6.6)	47.1	50.2	3.1 (3.0, 3.2)	60.2	55.0	-5.2 (-5.2, -5.3)	36.8	36.2	-0.6 (-0.6, -0.6)
Canada	44.2	55.2	11.0 (10.9, 11.2)	53.3	47.9	-5.4 (-5.4, -5.5)	49.4	58.5	9.1 (9.0, 9.2)	38.5	42.4	3.9 (3.8,4.0)
Denmark	53.7	67.0	13.3 (13.1, 13.5)	42.1	35.4	-6.7 (-6.7, -6.7)	63.5	72.6	9.1 (9.0, 9.2)	37.5	39.6	2.1 (2.0, 2.2)
Finland	36.6	57.0	20.4 (20.2, 20.7)	57.3	47.2	-10.1 (-10.2, -10.0)	47.3	53.8	6.5 (6.4, 6.6)	34.0	35.1	1.1 (1.1, 1.2)
France	25.0	39.2	14.2 (14.0, 14.4)	66.2	55.2	-11 (-11.1, -10.9)	36.3	38.1	1.8 (1.7, 1.9)	43.1	41.8	-1.3 (-1.3, -1.3)
Germany	40.0	53.0	13.0 (12.8, 13.2)	51.7	50.8	-0.9 (-0.9, -0.9)	56.1	57.3	1.2 (1.1, 1.3)	37.9	38.4	0.5 (0.5, 0.6)
Italy	40.7	56.1	15.4 (15.2, 15.6)	48.4	40.8	-7.6 (-7.6, -7.6)	44.2	52.5	8.3 (8.2, 8.4)	46.8	45.2	-1.6 (-1.6, -1.6)
Japan	39.1	39.9	0.8 (0.7, 0.9)	64.7	66.1	1.4 (1.3, 1.5)	43.6	48.7	5.1 (5.0, 5.2)	67.3	69.9	2.6 (2.5, 2.7)
Netherlands	44.6	63.1	18.5 (18.3, 18.8)	46.6	41.3	-5.3 (-5.3, -5.3)	47.3	56.6	9.3 (9.1, 9.5)	28.7	34.6	5.9 (5.8, 6.0)
Norway	41.9	56.5	14.6 (14.4, 14.8)	49.9	44.0	-5.9 (-5.9, -5.9)	54.1	57.0	2.9 (2.8, 3.0)	41.1	40.7	-0.4 (-0.4, -0.4)
Singapore	36.1	34.8	-1.3 (-1.3, -1.3)	58.9	63.6	4.7 (4.6, 4.8)	64.2	60.3	-3.9 (-3.9, -3.9)	47.8	49.2	1.4 (1.3, 1.5)
South Korea	48.7	43.7	-5.0 (-5.0, -5.0)	55.7	57.6	1.9 (1.8, 2.0)	54.7	53.6	-1.1 (-1.2, -1.1)	55.1	58.3	3.2 (3.1, 3.3)
Spain	28.0	52.1	24.1 (23.8, 24.4)	66.7	57.4	-9.3 (-9.4, -9.3)	41.0	54.8	13.8 (13.6, 14.0)	60.1	66.0	5.9 (5.8, 6.0)
Sweden	34.9	57.6	22.7 (22.4, 23.0)	54.4	41.2	-13.2 (-13.3, -13.1)	43.0	50.6	7.6 (7.5, 7.7)	40.0	38.3	-1.7 (-1.7, -1.7)
United Kingdom	54.3	77.5	23.2 (22.9, 23.5)	46.3	28.0	-18.3 (-18.4, -18.2)	50.7	70.5	19.8 (19.6, 20.0)	44.2	50.1	5.9 (5.8, 6.0)

348
349
350
351
352
353
354
355

356 **Table 3: Percentage ‘agreeing’ with COVID-19 related questions across population subgroups***

Population characteristics		% Would vaccinate		% Worried about side effects		% Believe government health authority will provide		% Worried about getting COVID-19	
		Wave 1 (median & low/high)	Wave 2 (median & low/high)	Wave 1 (median & low/high)	Wave 2 (median & low/high)	Wave 1 (median & low/high)	Wave 2 (median & low/high)	Wave 1 (median & low/high)	Wave 2 (median & low/high)
All		40.7 (25.0, 55.1)	55.2 (34.8, 77.5)	53.3 (42.1, 66.7)	47.9 (28.0, 66.1)	49.4 (36.3, 64.2)	55.0 (38.1, 72.6)	41.1 (28.7, 67.3)	41.8 (34.6, 69.9)
Sex									
	Male	46.5 (32.8, 60.5)	55.5 (39.2, 75.9)	44.8 (29.6, 59.3)	42.2 (24.1, 61.5)	51.3 (42.3, 63.7)	56.4 (42.7, 70.8)	37.6 (23.8, 62.4)	38.7 (28.7, 68.6)
	Female	35.0 (17.6, 50.0)	49.4 (30.2, 79.1)	58.4 (52.2, 74.6)	53.7 (31.8, 70.4)	47.3 (30.0, 64.6)	54.2 (34.0, 74.3)	45.4 (33.4, 71.9)	46.1 (35.5, 71.1)
Age group (years)									
	18-39	33.6 (19.5, 49.6)	42.1 (25.9, 71.7)	50.0 (42.1, 66.4)	50.8 (28.1, 60.7)	43.0 (29.3, 65.6)	49.8 (30.1, 64.8)	40.1 (24.8, 62.3)	36.1 (27.8, 61.4)
	40-64	40.8 (23.0, 58.3)	55.1 (35.6, 76.0)	55.4 (44.7, 67.8)	51.3 (30.7, 68.5)	49.6 (37.6, 63.5)	55.5 (39.7, 74.2)	42.0 (31.3, 67.3)	42.6 (31.2, 71.6)
	65+	54.8 (34.8, 71.9)	68.8 (50.6, 90.0)	50.8 (36.9, 73.1)	39.4 (23.4, 74.9)	62.7 (43.2, 80.3)	68.3 (47.5, 87.3)	45.2 (24.7, 75.4)	49.7 (35.0, 79.4)
Employment status									
	Working	41.7 (19.5, 52.9)	51.1 (34.4, 76.7)	53.3 (42.4, 66.9)	50.5 (26.7, 65.0)	45.7 (34.1, 62.9)	54.2 (34.3, 69.7)	41.6 (26.7, 68.9)	42.7 (33.9, 69.9)
	Student	38.8 (25.5, 52.1)	45.9 (22.8, 70.0)	50.3 (33.4, 59.9)	48.0 (13.1, 70.7)	51.1 (35.3, 70.8)	54.7 (45.4, 74.3)	41.1 (27.2, 53.7)	44.7 (27.4, 70.7)
	Retired	52.4 (34.1, 67.2)	67.8 (47.4, 90.2)	51.7 (38.8, 72.4)	45.0 (24.6, 82.4)	61.1 (43.0, 72.8)	67.1 (50.9, 82.5)	47.7 (25.9, 78.5)	51.2 (34.0, 100)
	Not working/Unemployed	34.9 (25.3, 54.2)	48.9 (18.8, 67.0)	55.4 (42.1, 73.5)	53.3 (35.4, 73.8)	44.3 (29.7, 69.9)	51.3 (24.9, 72.6)	41.1 (33.7, 66.5)	40.7 (32.7, 68.4)
Child in house									
	Yes	38.2 (21.4, 53.5)	46.5 (32.4, 68.9)	54.6 (40.3, 68.6)	55.8 (36.5, 64.7)	43.5 (32.7, 63.2)	51.5 (34.2, 63.2)	39.9 (29.7, 79.4)	40.5 (30.1, 69.6)
	No	43.2 (27.9, 58.0)	56.2 (34.6, 80.4)	51.5 (42.8, 66.7)	46.2 (25.0, 66.7)	53.5 (39.6, 65.1)	57.8 (41.8, 75.9)	43.7 (27.9, 65.2)	44.4 (28.9, 70.0)
	Prefer not to say/Other	32.5 (22.4, 51.9)	37.2 (19.1, 78.7)	56.1 (20.2, 100)	54.8 (24.5, 100)	41.7 (24.5, 100)	49.6 (36.9, 60.4)	35.1 (19.3, 100)	47.9 (9.3, 77.1)
Long-term health condition									
	Yes	47.7 (29.2, 61.9)	60.0 (40.6, 82.4)	53.6 (44.6, 69.4)	45.1 (28.4, 73.7)	53.0 (39.6, 70.3)	59.5 (42.6, 77.1)	47.6 (37.2, 70.9)	49.1 (35.4, 79.2)
	No	35.9 (22.6, 50.6)	47.5 (32.3, 72.4)	53.7 (40.1, 66.5)	49.7 (27.3, 64.1)	45.6 (34.9, 61.6)	53.1 (36.0, 69.3)	35.2 (21.3, 65.2)	35.3 (27.8, 64.5)
	Prefer not to say/Other	36.4 (15.3, 64.2)	48.6 (30.1, 76.0)	51.4 (31.0, 70.1)	49.9 (34.2, 65.7)	43.3 (18.0, 74.3)	51.3 (27.7, 70.1)	43.7 (21.7, 59.3)	41.6 (18.1, 62.5)
Frontline worker									
	Yes	39.6 (22.5, 52.9)	53.6 (36.9, 80.3)	53.0 (39.0, 67.4)	45.9 (23.8, 65.0)	47.2 (34.2, 65.8)	56.5 (36.8, 73.9)	42.2 (24.4, 64.5)	40.1 (33.4, 64.0)
	No	41.0 (18.2, 53.9)	50.3 (33.4, 72.1)	52.9 (41.0, 66.8)	51.4 (30.2, 65.0)	46.9 (33.3, 61.6)	52.8 (33.4, 66.9)	38.2 (27.8, 70.2)	37.5 (31.1, 72.8)
	Prefer not to say/Other	45.6 (28.8, 59.2)	56.9 (35.7, 78.6)	52.5 (41.7, 66.8)	45.9 (29.6, 68.6)	53.9 (38.4, 67.5)	56.1 (42.2, 77.6)	44.5 (31.4, 65.2)	47.3 (35.3, 69.9)

*Median % (and high/low) for the sample of 15 countries

357
358
359
360
361
362

363 **Figure 1: Change in those worried about getting COVID-19**

364

365

366

367

368

369

370

371

372

373 **Figure 2: Change in those who ‘agree’ with getting vaccine**

374

375

376

377

378

379

380

381

382 **Figure 3: Change in those who ‘agree’ with worried about side-effects of vaccine**

383

384

385

386

387

388

389

390

391 **Figure 4: Change in those who ‘agree’ Government health authorities will provide**
392 **effective vaccine**

393

394

395

396

397

398


399 **References**

400

- 401 1. Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. *Immunity*
402 2020;52(5):737-41.
- 403 2. Neumann-Böhme S, Varghese NE, Sabat I, et al. Once we have it, will we use it? A
404 European survey on willingness to be vaccinated against COVID-19: Springer, 2020.
- 405 3. Murphy J, Vallières F, Bentall RP, et al. Preparing for a COVID-19 vaccine: Identifying and
406 psychologically profiling those who are vaccine hesitant or resistant in two general
407 population samples. 2020
- 408 4. Ward JK, Alleaume C, Peretti-Watel P, et al. The French public's attitudes to a future
409 COVID-19 vaccine: The politicization of a public health issue. *Social science &*
410 *medicine* 2020;265:113414.
- 411 5. Malik AA, McFadden SM, Elharake J, et al. Determinants of COVID-19 vaccine acceptance
412 in the US. *EClinicalMedicine* 2020;26:100495.
- 413 6. Murphy J, Vallières F, Bentall RP, et al. Psychological characteristics associated with
414 COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom.
415 *Nature communications* 2021;12(1):1-15.
- 416 7. Paul E, Steptoe A, Fancourt D. Attitudes towards vaccines and intention to vaccinate
417 against COVID-19: Implications for public health communications. *The Lancet*
418 *Regional Health-Europe* 2020:100012.
- 419 8. Thunstrom L, Ashworth M, Finnoff D, et al. Hesitancy towards a COVID-19 vaccine and
420 prospects for herd immunity. *Available at SSRN 3593098* 2020
- 421 9. Karlsson LC, Soveri A, Lewandowsky S, et al. Fearing the disease or the vaccine: The case
422 of COVID-19. *Personality and individual differences* 2021;172:110590.
- 423 10. Wilson E, Donovan CV, Campbell M, et al. Multiple COVID-19 clusters on a university
424 campus—North Carolina, August 2020. *Morbidity and Mortality Weekly Report*
425 2020;69(39):1416.
- 426 11. Rajmil L. Role of children in the transmission of the COVID-19 pandemic: a rapid scoping
427 review. *BMJ Paediatr Open* 2020;4(1):e000722. doi: 10.1136/bmjpo-2020-000722
428 [published Online First: 2020/07/01]
- 429 12. de Souza TH, Nadal JA, Nogueira RJ, et al. Clinical manifestations of children with
430 COVID-19: a systematic review. *Pediatric pulmonology* 2020;55(8):1892-99.
- 431 13. Olson O, Berry C, Kumar N. Addressing Parental Vaccine Hesitancy towards Childhood
432 Vaccines in the United States: A Systematic Literature Review of Communication
433 Interventions and Strategies. *Vaccines (Basel)* 2020;8(4) doi:
434 10.3390/vaccines8040590 [published Online First: 2020/10/15]
- 435 14. Jarrett C, Wilson R, O'Leary M, et al. Strategies for addressing vaccine hesitancy - A
436 systematic review. *Vaccine* 2015;33(34):4180-90. doi: 10.1016/j.vaccine.2015.04.040
437 [published Online First: 2015/04/22]
- 438 15. Prevention ECfD, Control. Catalogue of interventions addressing vaccine hesitancy: ECDC
439 Stockholm, Germany, 2017.


440

If a Covid-19 vaccine were made available to me this week, I would definitely get it




Change No data ≥5% decrease 0-5% decrease 0-5% increase ≥5% increase

I am worried about potential side effects of a COVID19 vaccine



Change No data ≥5% decrease 0-5% decrease 0-5% increase ≥5% increase

I believe government health authorities in my country will provide me with an effective COVID19 vaccine



Change No data ≥5% decrease 0-5% decrease 0-5% increase ≥5% increase